SaVi Pharmaceutical Joint Stock Company

SaVipharm has over a decade of experience as a leading Vietnamese pharmaceutical company with EU-GMP and Japanese GMP certifications. It manufactures more than two hundred licensed pharmaceutical products across multiple therapeutic areas. The company has developed at least twelve new drug groups and submitted over four hundred generic dossiers to the Ministry of Health. Its high-tech R&D center focuses on advanced formulations including microgranular technologies and oncology drugs. Notably, it has developed a COVID‑19 treatment medicine that awaits mass manufacturing approval. The company maintains strategic partnerships with global firms such as GSK for quality management systems and exports to Japan since at least 2010.[1][2][3][4][5]